CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc > Globe says Graycliff, others hit by shady promotions

<< Previous

Bullboard Posts

Next >>

Comment by NNick99on Apr 15, 2021 11:00am

195 Views

Post# 33000300

RE:Globe says Graycliff, others hit by shady promotions

Agree. Bought 3000 shared at 1,41 last week. Lost almost 50percent in a week. Come on. We work hard and these people manipulating market and wrong info should be punished.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks